QIAGEN Announces Third Co-Development Program for Companion Diagnostics Paired with Lilly’s Investigational Cancer Compounds

QIAGEN yesterday announced an agreement with Eli Lilly and Company to develop and commercialize a molecular companion diagnostic paired with a novel Lilly oncology compound.

This is the third co-development project by QIAGEN and Lilly to create companion diagnostics, which are tests that analyze genomic information in patient samples to enable personalized decisions on treatments. The latest collaboration, involving an undisclosed Lilly compound and an undisclosed molecular diagnostic target, builds on a master collaboration agreement for development of tailored therapies in cancer and other therapeutic areas signed earlier this year.

QIAGEN and Lilly are long-standing partners in personalized healthcare. QIAGEN’s therascreen® KRAS RGQ PCR Kit has been widely adopted by laboratories since its July 2012 approval by the Food and Drug Administration (FDA) as a companion diagnostic. The therascreen KRAS Test detects gene mutations in metastatic colorectal cancer patients, indicating which ones will benefit from Erbitux. In September 2011, QIAGEN and Lilly partnered to develop a companion diagnostic that evaluates the Janus kinase 2 (JAK2) gene, which plays a role in some blood cancers. The test is paired with a Lilly compound to guide use of the proposed drug, currently in clinical trials.

"We are pleased to partner with Lilly on a third development program to improve life for cancer patients through companion diagnostics that guide the use of novel targeted medications. QIAGEN is a preferred partner for leading pharmaceutical companies like Lilly because our validated development processes and regulatory track record provide an accelerated path to commercialization,” said Peer Schatz, QIAGEN’s Chief Executive Officer. “Using standardized, well-validated processes to develop and commercialize companion diagnostics reduces the risks in drug development for Pharma companies. Once approved, our therascreen tests have a ready path to commercial adoption since laboratories around the world have embraced QIAGEN’s efficient QIAsymphony automation platform."

"Partnering with QIAGEN on this program enables Lilly to continue to advance our goal of providing tailored therapies to patients in need," said Daniel Skovronsky, M.D., Ph.D., vice president, tailored therapeutics, Lilly and CEO, Avid Radiopharmaceuticals, Lilly’s wholly owned molecular imaging subsidiary. “The QIAGEN and Lilly teams have formed strong working relationships and we look forward to working with QIAGEN to advance this latest innovation together.”

The Lilly co-development program and others are designing companion diagnostics that offer laboratories an efficient workflow on QIAGEN’s Rotor-Gene Q MDx instrument using real-time PCR technology. The Rotor-Gene Q MDx is part of the QIAsymphony family of automated platforms.